CSL730 + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Immune Complex-mediated Autoimmune Diseases
Conditions
Immune Complex-mediated Autoimmune Diseases
Trial Timeline
Sep 23, 2020 → Mar 28, 2023
NCT ID
NCT04446000About CSL730 + Placebo
CSL730 + Placebo is a phase 1 stage product being developed by CSL for Immune Complex-mediated Autoimmune Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT04446000. Target conditions include Immune Complex-mediated Autoimmune Diseases.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04446000 | Phase 1 | Terminated |
Competing Products
20 competing products in Immune Complex-mediated Autoimmune Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Placebo + Lusutrombopag | Shionogi | Phase 2 | 52 |
| Lusutrombopag | Shionogi | Phase 2 | 52 |
| Romiplostim | Kyowa Kirin | Phase 1/2 | 41 |
| AMG 531 | Kyowa Kirin | Phase 2/3 | 65 |
| Romiplostim + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Romiplostim (AMG-531) | Kyowa Kirin | Phase 2 | 52 |
| Romiplostim and danazol | Kyowa Kirin | Phase 2 | 52 |
| Hetrombopag Olamine | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Herombopag | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zostavax® | Merck | Pre-clinical | 23 |
| Raltegravir + Atazanavir | Merck | Pre-clinical | 23 |
| Zostavax | Merck | Pre-clinical | 23 |
| MK-8723 + Matching Placebo | Merck | Phase 1 | 33 |